Table 1.
Relationships between ELK1 expression and clinical features.
| Clinical features | N | ELK1 positive | ELK1 negative | Positive rate (%) | χ2 | P |
|---|---|---|---|---|---|---|
| Para cancer | 57 | 21 | 36 | 36.8 | 5.937 | 0.015* |
| Breast cancer | 57 | 34 | 23 | 59.6 | ||
| Age | ||||||
| ≤55 | 26 | 17 | 9 | 65.4 | 0.653 | 0.419 |
| >55 | 31 | 17 | 14 | 54.8 | ||
| Stage | ||||||
| I+II | 38 | 24 | 14 | 63.2 | 0.583 | 0.445 |
| III+IV | 19 | 10 | 9 | 52.6 | ||
| Lymphatic | ||||||
| Positive | 26 | 19 | 7 | 73.1 | 4.520 | 0.033* |
| Negative | 31 | 14 | 17 | 45.2 | ||
| ER | ||||||
| Positive | 42 | 24 | 18 | 57.1 | 1.222 | 0.269 |
| Negative | 15 | 11 | 4 | 73.3 | ||
| PR | ||||||
| Positive | 37 | 24 | 13 | 64.9 | 1.192 | 0.275 |
| Negative | 20 | 10 | 10 | 50.0 | ||
| Her-2 | ||||||
| Positive | 47 | 27 | 20 | 57.4 | 0.144 | 0.704 |
| Negative | 10 | 7 | 3 | 70.0 | ||
| Ki-67 | ||||||
| Positive | 51 | 31 | 20 | 60.8 | 0.005 | 0.945 |
| Negative | 6 | 3 | 3 | 50.0 | ||
*
Statistical significance (P < 0.05).
ELK1, ETS-like gene 1; ER, estrogen receptor; Her-2, human epidermal growth factor receptor-2; N, number; PR, progesterone receptor.